Qiuping Qin

Prof. Qiuping Qin

Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Qiuping QinQiuping Qin
Qiuping Qin
LGLikun Gong
Likun Gong
Antibody–drug conjugates (ADCs) are a new class of biotherapeutics, consisting of a cytotoxic payload covalently bound to an antibody by a linker. Ligand-binding assay (LBA) and liquid chromatography-mass spectrometry (LC-MS) are the favored techniques for the analysis of ADCs in biomatrices. The goal of our review is to provide current strategies related to a series of bioanalytical assays for pharmacokinetics (PK) and anti-drug antibody (ADA) assessments. Furthermore, the strengths and limitations of LBA and LC-MS platforms are compared. Finally, potential factors that affect the performance of the developed assays are also provided. It is hoped that the review can provide valuable insights to bioanalytical scientists on the use of an integrated analytical strategy involving LBA and LC–MS for the bioanalysis of ADCs and related immunogenicity evaluation.

18 March 2025 in Antibody Therapeutics
Verified
Journal Article
Open access
YCYumei Cheng
Yumei Cheng
JLJing Lu
Jing Lu
CZChonghao Zhang
Chonghao Zhang
WYWeiyuan Yan
Weiyuan Yan
PZPanpan Zhu
Panpan Zhu
Likun GongLikun Gong
Likun Gong
An antibody–drug conjugate (ADC), consisting of an antibody, a chemical linker, and a payload, can selectively deliver a highly cytotoxic payload to cancer cells and minimize the systemic toxicity of the payload by harnessing the selectivity of the antibody. However, many ADCs have unacceptable toxic effects due to the expression characteristics of target antigens, structural characteristics of antibodies, linker stability and payload properties, which have slowed their development progress. In this review, we describe the effects of the structure of each component of an ADC molecule on its toxicity, explore and discuss the toxicity profiles of various ADCs in the main body tissues/organs by using nonclinical and clinical data obtained from marketed ADCs, aiming to provide a reference for the development of novel ADC molecules and to facilitate related nonclinical and clinical studies.

1 February 2022 in Cell Discovery
Verified
Journal Article
Open access
PDF file
YLYiru Long
Yiru Long
JSJianhua Sun
Jianhua Sun
TSTian-Zhang Song
Tian-Zhang Song
TLTingting Liu
Tingting Liu
FTFeng Tang
Feng Tang
Likun GongLikun Gong
Likun Gong
Safe, effective, and economical vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed to achieve adequate herd immunity and end the pandemic. We constructed a novel SARS-CoV-2 vaccine, CoVac501, which is a self-adjuvanting peptide vaccine conjugated with Toll-like receptor 7 (TLR7) agonists. The vaccine contains immunodominant peptides screened from the receptor-binding domain (RBD) and is fully chemically synthesized. It has been formulated in an optimized nanoemulsion formulation and is stable at 40 °C for 1 month. In non-human primates (NHPs), CoVac501 elicited high and persistent titers of protective neutralizing antibodies against multiple RBD mutations, SARS-CoV-2 original strain, and variants (B.1.1.7 and B.1.617.2). Specific peptides booster immunization against the B.1.351 variant has also been shown to be effective in improving protection against B.1.351. Meanwhile, CoVac501 elicited the increase of memory T cells, antigen-specific CD8+ T-cell responses, and Th1-biased CD4+ T-cell immune responses in NHPs. Notably, at an extremely high SARS-CoV-2 challenge dose of 1 × 107 TCID50, CoVac501 provided near-complete protection for the upper and lower respiratory tracts of cynomolgus macaques.

10 December 2003 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
MCMichael Christiansen
Michael Christiansen
SLSo Larsen
So Larsen
COC Oxvig
C Oxvig
Qiuping QinQiuping Qin
Qiuping Qin
JWJm Wagner
Jm Wagner
BNB Nørgaard‐Pedersen
B Nørgaard‐Pedersen

2 September 2022 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
LZLiping Zhou
Liping Zhou
TLTingting Liu
Tingting Liu
MMMengxia Mo
Mengxia Mo
YSYulong Shi
Yulong Shi
LWLeyun Wu
Leyun Wu
Zhijian XuZhijian Xu
Zhijian Xu

24 November 2021 in Journal of Pharmaceutical Analysis
Verified
Journal Article
Open access
MPMin Pei
Min Pei
TLTingting Liu
Tingting Liu
LOLu Ouyang
Lu Ouyang
JSJianhua Sun
Jianhua Sun
XDXiaojie Deng
Xiaojie Deng
CWChunhe Wang
Chunhe Wang
Antibody-drug conjugates (ADCs) are commonly heterogeneous and require extensive assessment of exposure-efficacy and exposure-safety relationships in preclinical and clinical studies. In this study, we report the generation of a monoclonal antibody against monomethyl auristatin E (MMAE) and the development, validation, and application of sensitive and high-throughput enzyme-linked immunosorbent assays (ELISA) to measure the concentrations of MMAE-conjugated ADCs and total antibodies (tAb, antibodies in ADC plus unconjugated antibodies) in cynomolgus monkey sera. These assays were successfully applied to in vitro plasma stability and pharmacokinetic (PK) studies of SMADC001, an MMAE-conjugated ADC against trophoblast cell surface antigen 2 (TROP-2). The plasma stability of SMADC001 was better than that of similar ADCs coupled with PEG4-Val-Cit, Lys (m-dPEG24)-Cit, and Val-Cit linkers. The developed ELISA methods for the calibration standards of ADC and tAb revealed a correlation between serum concentrations and the OD450 values, with R2 at 1.000, and the dynamic range was 0.3–35.0 ng/mL and 0.2–22.0 ng/mL, respectively; the intra- and inter-assay accuracy bias% ranged from −12.2% to −5.2%, precision ranged from −12.4% to −1.4%, and the relative standard deviation (RSD) was less than 6.6% and 8.7%, respectively. The total error was less than 20.4%. The development and validation steps of these two assays met the acceptance criteria for all addressed validation parameters, which suggested that these can be applied to quantify MMAE-conjugated ADCs, as well as in PK studies. Furthermore, these assays can be easily adopted for development of other similar immunoassays.